Chemotherapy for Lung Cancer in the Era of Personalized Medicine
- Author:
Seung Hyeun LEE
1
Author Information
- Publication Type:Review
- Keywords: Chemotherapy; Lung Neoplasms; Precision Medicine; Molecular Targeted Therapy; Immunotherapy; History; Evolution
- MeSH: Drug Therapy; Humans; Immunotherapy; Lung Neoplasms; Lung; Molecular Targeted Therapy; Precision Medicine; Protein-Tyrosine Kinases; Quality of Life; Standard of Care
- From:Tuberculosis and Respiratory Diseases 2019;82(3):179-189
- CountryRepublic of Korea
- Language:English
- Abstract: Although recent advances in molecular targeted therapy and immuno-oncology have revolutionized the landscape of lung cancer therapeutics, cytotoxic chemotherapy remains an essential component of lung cancer treatment. Extensive evidence has demonstrated the clinical benefit of chemotherapy, either alone or in combination with other treatment modalities, on survival and quality of life of patients with early and advanced lung cancer. Combinational approaches with other classes of anti-neoplastic agents and new drug-delivery systems have revealed promising data and are areas of active investigation. Chemotherapy is recommended as a standard of care in patients that have progressed after tyrosine kinase inhibitors or immune checkpoint inhibitors. Chemotherapy remains the fundamental means of lung cancer management and keeps expanding its clinical implication. This review will discuss the current position and future role of chemotherapy, and specific consideration for its clinical application in the era of precision medicine.
